News Release

– First Automated Insulin Delivery System in the World to Feature Dexcom’s Most Advanced CGM Technology –

SAN DIEGO--(BUSINESS WIRE)--Dec. 6, 2023-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the launch of updated t:slim X2™ insulin pump software with Dexcom G7 Continuous Glucose Monitoring (CGM) integration in the United States. Tandem’s #1-rated automated insulin delivery (AID) system* with Control-IQ technology is the only AID option in the world today to use Dexcom’s latest CGM technology.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231206939624/en/

t:slim X2 Insulin Pump from Tandem Diabetes Care with Dexcom G7 CGM Integration (Photo: Business Wire)

Tandem will email instructions to all in-warranty t:slim X2 users in the United States to offer the option to add the new feature free of charge via remote software update. t:slim X2 pumps pre-loaded with the updated software are now shipping to new customers.

“With this launch we are offering more than 300,000 current t:slim X2 users the ability to integrate with Dexcom’s most advanced CGM technology, demonstrating our commitment to continued leadership in advancing AID systems,” said John Sheridan, president and chief executive officer of Tandem Diabetes Care. “As we celebrate our 10-year partnership with Dexcom, we remain committed to sustaining our rapid pace of innovation to further our mission of helping improve the lives of people with diabetes.”

With the integration of Dexcom G7, t:slim X2 insulin pump users can now:

• Spend more time in closed loop with little to no wait time between Dexcom G7 CGM sensor sessions.**
• Use either a Dexcom G6 or Dexcom G7 CGM sensor, allowing even more choice in their diabetes management.

Dexcom G7, which is 60 percent smaller than its Dexcom G6 predecessor, offers a range of new features, including:

• Improved accuracy***
• A 30-minute sensor warmup time, compared to 2 hours previously
• A 12-hour grace period to replace finished sensors for a more seamless transition between sessions and flexibility for when to change sensors

“The Dexcom G7 and t:slim X2 insulin pump integration is the culmination of years of partnership and a shared commitment to improve the lives of people with diabetes,” said Jake Leach, executive vice president and chief operating officer at Dexcom. “We’re excited to bring our newest technology to Tandem users so they can experience the benefits of the smallest, most accurate, easy to use CGM connected to AID systems.”

For additional product and safety information, or to begin the order process for a new Tandem pump with Dexcom G7 integration, visit tandemdiabetes.com/products.

Information about the software update process for existing in-warranty pump users, including system requirements, is available at tandemdiabetes.com/G7update.

The t:slim X2 pump with Dexcom G7 integration is expected to launch in additional countries outside the U.S. in early 2024.

* dQ&A US Q1 2023 Diabetes Connections Patient Panel Report
** No wait time claim based on user inserting a new, unpaired Dexcom G7 at least 30 minutes before the old, paired Dexcom G7 sensor expires. See User Guide for more details on the sensor start process.
*** Dexcom, data on file, 2022.

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc., a global insulin delivery and diabetes technology company based in San Diego, California, creates new possibilities for people living with diabetes, their loved ones, and healthcare providers through a positively different experience. The company’s human-centered approach to design, development, and support delivers innovative products and services for people who use insulin. Tandem manufactures and sells the t:slim X2 insulin pump with Control-IQ technology. For more information, visit tandemdiabetes.com.

Follow Tandem Diabetes Care on Twitter @tandemdiabetes; use #tslimX2 and #TandemDiabetes.
Follow Tandem Diabetes Care on Facebook at facebook.com/TandemDiabetes.
Follow Tandem Diabetes Care on LinkedIn at linkedin.com/company/tandemdiabetes.

Forward-looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements relate to, among other things, the anticipated timing for the international availability of the t:slim X2 pump with Dexcom G7 integration as well as our ability to provide the software update for current t:slim X2 pump users and the t:slim X2 pumps pre-loaded with Dexcom G7 integration software. These statements are subject to numerous risks and uncertainties, including our ability to start commercial scale manufacturing of the t:slim X2 pumps pre-loaded with Dexcom G7 integration software, our ability to operate and maintain a system to facilitate online training for existing t:slim X2 pump customers upgrading their existing devices, and the risk that we may encounter other challenges that may delay the availability of t:slim X2 pumps pre-loaded with Dexcom G7 integration software. These and other risks are identified and described in greater detail under the “Risk Factors” heading of our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and other documents filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Actual results could differ materially from those anticipated or projected in the forward-looking statements. Tandem undertakes no obligation to update or review any forward-looking statement in this press release because of new information, future events, or other factors.

Responsible use of Control-IQ technology

Control-IQ technology does not prevent all highs and lows. Users must still bolus for meals and actively manage their diabetes. Visit tandemdiabetes.com/safetyinfo for additional important safety information.

Important Safety Information: RX ONLY. The t:slim X2 pump and Control-IQ technology are intended for single patient use. The t:slim X2 pump and Control-IQ technology are indicated for use with NovoLog or Humalog U-100 insulin. t:slim X2 insulin pump: The t:slim X2 insulin pump with interoperable technology is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in people requiring insulin. The pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. The pump is indicated for use in individuals 6 years of age and greater. Control-IQ technology: Control-IQ technology is intended for use with compatible integrated continuous glucose monitors (iCGM, sold separately) and alternate controller enabled (ACE) pumps to automatically increase, decrease, and suspend delivery of basal insulin based on iCGM readings and predicted glucose values. It can also deliver correction boluses when the glucose value is predicted to exceed a predefined threshold. Control-IQ technology is intended for the management of Type 1 diabetes mellitus in persons 6 years of age and greater.

WARNING: Control-IQ technology should not be used by anyone under the age of 6 years old. It should also not be used in patients who require less than 10 units of insulin per day or who weigh less than 55 pounds.

Control-IQ technology is not indicated for use in pregnant women, people on dialysis, or critically ill patients. Do not use Control-IQ technology if using hydroxyurea. Users of the t:slim X2 pump and Control-IQ technology must: use the insulin pump, CGM, and all other system components in accordance with their respective instructions for use; test blood glucose levels as recommended by their healthcare provider; demonstrate adequate carb-counting skills; maintain sufficient diabetes self-care skills; see healthcare provider(s) regularly; and have adequate vision and/or hearing to recognize all functions of the pump, including alerts, alarms, and reminders. The t:slim X2 pump must be removed before MRI, CT, or diathermy treatment. Visit tandemdiabetes.com/safetyinfo for additional important safety information.

© 2023 Tandem Diabetes Care, Inc. All rights reserved. Tandem Diabetes Care, the Tandem logo, Control-IQ, and t:slim X2 are either registered trademarks or trademarks of Tandem Diabetes Care, Inc. in the United States and/or other countries. All third-party marks are the property of their respective owners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231206939624/en/

Tandem Diabetes Care Media Contact:
858-366-6900
media@tandemdiabetes.com

Tandem Diabetes Care Investor Contact:
858-366-6900
IR@tandemdiabetes.com

Source: Tandem Diabetes Care, Inc.